These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25468910)

  • 1. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.
    Ward MD; Leahy DJ
    J Biol Chem; 2015 Jan; 290(3):1570-9. PubMed ID: 25468910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging.
    Macdonald-Obermann JL; Piwnica-Worms D; Pike LJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):137-42. PubMed ID: 22190492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single ligand is sufficient to activate EGFR dimers.
    Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB Receptors and Cancer.
    Wang Z
    Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
    Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
    Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
    Mendrola JM; Berger MB; King MC; Lemmon MA
    J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.
    Fan YX; Wong L; Johnson GR
    Biochem J; 2005 Dec; 392(Pt 3):417-23. PubMed ID: 16122376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
    Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
    J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.
    Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ
    J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
    Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.
    Macdonald-Obermann JL; Pike LJ
    J Biol Chem; 2014 Sep; 289(38):26178-26188. PubMed ID: 25086039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
    Schmidt M; Wels W
    Int J Cancer; 2002 Jan; 97(3):349-56. PubMed ID: 11774287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.